Torticollis
Drug research and approvals for torticollis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 11 studies of torticollis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 11
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Theta Burst Transcranial Focused Ultrasound as a Novel Treatment for Cervical DystoniaNCT07690514 · Not applicable · Robert Chen · starts Nov 18, 2024
- Noninvasive Brain Stimulation for Cervical DystoniaNCT07681284 · Not applicable · Fondazione Policlinico Universitario Campus Bio-Medico · starts Jul 6, 2026
- A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated DystoniaNCT07304089 · Phase 2 · Vima Therapeutics · starts Feb 5, 2026
- Effect of Vibro-tactile Stimulation Intensity on Head Posture in Cervical DystoniaNCT07245615 · Not applicable · University of Minnesota · starts Mar 10, 2025
- UltraSound-Guided Versus Non-Ultrasound-Guided Botulinum Toxin Injections in Cervical Dystonia [CUSTODY]NCT07233993 · Not applicable · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · starts Nov 1, 2025
- Zinc as an Adjunctive Therapy for Cervical DystoniaNCT07140874 · Phase 2 · University of Florida · starts Jun 1, 2026
- A Study of IPN10200 for the Treatment of Cervical Dystonia in AdultsNCT06937931 · Phase 2 · Ipsen · starts Jun 30, 2025
- Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical DystoniaNCT06771323 · Phase 2 · Virginia Commonwealth University · starts Dec 17, 2024
- Effectiveness of Repositioning and Cranial Remolding in Infants With Cranial DeformationNCT05917678 · Not applicable · University of Texas Southwestern Medical Center · starts May 23, 2023
Approved 1
- RimabotulinumtoxinbVesicle-associated membrane protein 2 inhibitor
Phase 3 4
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Botulinum toxin type aSynaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme
- DaxibotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- IncobotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Phase 2 3
- Prabotulinumtoxin aSynaptosomal nerve-associated protein 25 (SNAP-25) proteolytic enzyme
- LevetiracetamSynaptic vesicle glycoprotein 2A modulator
- DronabinolCannabinoid CB1 receptor agonist
Phase 1 or earlier 1
- PerampanelGlutamate receptor ionotropic AMPA antagonist
How its trials ended
126 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 29 whose ending is known, 66% met their primary endpoint, 0% missed it and 34% stopped early.
- Completed, result not reported6955%
- Met its primary endpoint1915%
- Status unknown1613%
- Ongoing1210%
- Stopped: enrollment or feasibility43%
- Stopped: other or unclear43%
- Stopped: sponsor or business decision22%
| Aug 12, 1998 | Botulinum toxin type ATreatment of spasmodic torticollis (cervical dystonia). | Ipsen Biopharm Limited | Designated |
| Oct 24, 1991 | Botulinum toxin type FTreatment of spasmodic torticollis (cervical dystonia). | Ipsen Limited | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA